InauguralInvitation Only
Gynecologic Cancers
USFocus Meeting 2027
Two days, 52 people, one room.
April 23 to 24, 2027
The Ballantyne, Charlotte, NC
Dates
April 23-24, 2027
Two-day program
Venue
The Ballantyne
Charlotte, NC
Audience
26 KOLs & 26 fellows
52 by invitation
Format
Plenary, panels + cases
8 sessions · 25 talks
A Curated Room: The People Shaping Practice
This inaugural, invitation-only meeting convenes a deliberately small faculty: 26 leading gynecologic oncology KOLs alongside 26 hand-selected fellows and junior faculty, the clinicians defining today’s standards and the ones who will define the next decade’s, in one room for two days.
The science tracks where treatment is moving: antibody-drug conjugates across every tumor type, biomarker-driven selection, IO in dMMR disease, and emerging targeted mechanisms. Every session pairs expert talks with a moderated panel and a case presentation, sustained, close-quarters engagement rather than a lecture hall.
Antibody-Drug ConjugatesBiomarker & HRD TestingIO in dMMRReplication-Stress AxisTCEs & BispecificsOvarian · Endometrial · Cervical
Meeting Co-Chairs
Bradley Monk
Florida Cancer Specialists, West Palm Beach, FL
Kathleen Moore
Fred & Pamela Buffett Cancer Center, Omaha, NE
Faculty Drawn From
MD Anderson · Memorial Sloan Kettering · Stanford · Dana-Farber · Massachusetts General and other leading US cancer centers
52
Invited attendees only, sustained access, not a crowd
1:1
KOLs to rising faculty, a hand-picked balance in every session
14
Established US Focus Meetings behind it, a proven platform, not a one-off
25
Talks across 8 sessions, each paired with a panel and a case
Gynecologic Cancers US Focus Meeting 2027
Faculty
Listed alphabetically by surname
Floor Backes
Ohio State University, Columbus, OH
Jubilee Brown
Atrium Health Levine Cancer Institute, Charlotte, NC
John Chan
Sutter Health/Palo Alto Medical Foundation, San Francisco, CA
Dana Chase
UCLA David Geffen School of Medicine, Los Angeles, CA
Brad Corr
University of Colorado Anschutz, Aurora, CO
Casey Cosgrove
Ohio State University, Columbus, OH
Ramez Eskander
UC San Diego, La Jolla, CA
Barrett Lawson
MD Anderson Cancer Center, Houston, TX
Ying Liu
Memorial Sloan Kettering, New York, NY
Patricia LoRusso
Yale Cancer Center, New Haven, CT
Jyoti Mayadev
UC San Diego, La Jolla, CA
Bradley Monk
Florida Cancer Specialists, West Palm Beach, FL
Kathleen Moore
Fred & Pamela Buffett Cancer Center, Omaha, NE
David O’Malley
Ohio State University, Columbus, OH
Rebecca Porter
Dana-Farber Cancer Institute, Boston, MA
Bhavana Pothuri
NYU Langone Health, New York, NY
BJ Rimel
Cedars-Sinai, Los Angeles, CA
Ritu Salani
UCLA, Los Angeles, CA
Brian Slomovitz
Mount Sinai Medical Center, Miami Beach, FL
Paolo Tarantino
Dana-Farber Cancer Institute, Boston, MA
Krishnansu Tewari
UC Irvine, Orange, CA
Shannon Westin
MD Anderson Cancer Center, Houston, TX
Timothy Yap
MD Anderson Cancer Center, Houston, TX
Oladapo Yeku
Massachusetts General Hospital, Boston, MA
Two Days, Eight Sessions
Agenda
Presentations15 min
Young Investigator Case Presentations5 min
Panel Discussions30 min
Coffee Breaks20 min
Lunch Breaks65 min
Day One · Friday, April 23, 2027
Plenary Presentation: Setting the Stage, Why, How Often & Which Tests
Casey CosgroveOhio State University, Columbus, OH
Session IMolecularly Driven Classification of Gynecologic Cancers
ModeratorTBC
Endometrial Molecular Classification
Casey CosgroveOhio State University, Columbus, OH
Multiplex Biomarker Workflow for Ovarian Cancer
Barrett LawsonMD Anderson Cancer Center, Houston, TX
HRD/BRCA Testing: Assays, Spatial Heterogeneity & Front-Line PARPi Access (± RNA/fusions)
Dana ChaseUCLA David Geffen School of Medicine, Los Angeles, CA
Young Investigator Case Presentation
TBD
Panel Discussion
Coffee Break
Session IICan IO Cure Advanced & Recurrent dMMR Endometrial Cancer?
ModeratorTBC
Adjuvant Therapy for dMMR (NRG-GY020 Readout)
Floor BackesOhio State University, Columbus, OH
Chemo/ICI in Advanced Recurrent Disease + Mechanisms of Resistance
Ramez EskanderUC San Diego, La Jolla, CA
ICI Instead of Chemo in dMMR
Brian SlomovitzMount Sinai Medical Center, Miami Beach, FL
Young Investigator Case Presentation
TBD
Panel Discussion
Lunch Break + Faculty and Fellow Photo
Session IIINon-dMMR Endometrial Cancer
ModeratorTBC
Adjuvant Therapy for pMMR by Molecular Subgroup (RAINBO, PORTEC-4)
Brad CorrUniversity of Colorado Anschutz, Aurora, CO
Non-dMMR Advanced Recurrent 1L & Optimal Maintenance
Kathleen MooreFred & Pamela Buffett Cancer Center, Omaha, NE
2L+ Endometrial Cancer ADCs & Small Molecules
Bhavana PothuriNYU Langone Health, New York, NY
Young Investigator Case Presentation
TBD
Panel Discussion
Coffee Break
Session IVThe ADC Era: Constructs & Off-Tumor Toxicity
ModeratorTBC
What ADCs Are: Beyond Target, Payload & Linker
Paolo TarantinoDana-Farber Cancer Institute, Boston, MA
Toxicities & Need for MDT: ILD, OM, Ocular
BJ RimelCedars-Sinai, Los Angeles, CA
Dose & Regimen Optimization, Including Duration
Bradley MonkFlorida Cancer Specialists, West Palm Beach, FL
Young Investigator Case Presentation
TBD
Panel Discussion
Day Two · Saturday, April 24, 2027
Session VOvarian Cancer: Front Line Considerations
ModeratorTBC
HRD+ Use of PARP Inhibitors
Ying LiuMemorial Sloan Kettering, New York, NY
HRD Test Negative: Bev vs No Bev; Trials to Watch
David O’MalleyOhio State University, Columbus, OH
Low-Grade Ovarian Cancer
Jubilee BrownAtrium Health Levine Cancer Institute, Charlotte, NC
Young Investigator Case Presentation
TBD
Panel Discussion
Coffee Break
Session VIOvarian Cancer: Recurrent
ModeratorTBC
Beyond PARP: The Replication-Stress Axis (ATR/WEE1/PKMYT1/CCNE1)
Timothy YapMD Anderson Cancer Center, Houston, TX
ADCs in PSOC and PROC: Mechanisms of Resistance
Rebecca PorterDana-Farber Cancer Institute, Boston, MA
Other Modalities in PROC: Working Up & Sequencing Options
John ChanSutter Health/Palo Alto Medical Foundation, San Francisco, CA
Young Investigator Case Presentation
TBD
Panel Discussion
Lunch Break + Faculty and Fellow Photo
Session VIICervical Cancer
ModeratorTBC
Local Regional Treatment, ICI & Unanswered Questions
Jyoti MayadevUC San Diego, La Jolla, CA
1st-Line Metastatic & Opportunities to Improve
Krishnansu TewariUC Irvine, Orange, CA
2L ADCs: Finally Something That Works
Ritu SalaniUCLA, Los Angeles, CA
Young Investigator Case Presentation
TBD
Panel Discussion
Coffee Break
Session VIIINew Modalities
ModeratorTBC
TCEs & Bispecifics
Oladapo YekuMassachusetts General Hospital, Boston, MA
Novel Small Molecules: KIF18A and Others
Shannon WestinMD Anderson Cancer Center, Houston, TX
ADCs with Multiple Targets and/or Multiple Payloads: Hope versus Hype
Patricia LoRussoYale Cancer Center, New Haven, CT
Young Investigator Case Presentation
TBD
Panel Discussion
Partnership Opportunities Now Open
Bespoke engagement packages for a closed, invitation-only audience
Request the Prospectus →